Article

Deloitte Releases 12th Annual Life Sciences Industry Accounting Guide

Author(s):

Pharmaceutical Executive Editorial Staff

Report provides comprehensive look at financial and accounting issues faced by life sciences industry.

On Mar. 16 Deloitte released its 12th annual Life Sciences Industry Accounting Guide. The report provides a comprehensive look at some of the complex issues that finance and accounting professionals in the life sciences industry face including R&D costs, acquisitions and divestitures, consolidation, contingencies, revenue recognition, income taxes, financial instruments, and financial statement presentation and disclosure.

Some of the main themes from this year’s edition include:

  • COVID-19-Related Accounting and Financial Reporting Considerations for Life Sciences Entities
  • IPOs and SPACs
  • Revenue Recognition
  • Structured Trade Payable Arrangement

For additional information and the full report, click here.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Matthew Yelovich, Cleary Gottlieb, Theranos Case
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Fred Aslan
Related Content
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 4th 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Credit: zimmytws | stock.adobe.com. Balancing profitability with affordability, redesigning supply chains for resilience, and engaging actively in trade policy discussions are no longer optional, they are strategic imperatives.
August 4th 2025

How Can Pharma Leadership Prepare for the Current Tariff Environment and Potential Changes in 2026?

Thani Jambulingam, PhD
The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.
Moderna to Reduce Workforce by 10% Amid Cost Restructuring
August 4th 2025

Moderna to Reduce Workforce by 10% Amid Cost Restructuring

Don Tracy, Associate Editor
Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets $1.5 billion in savings by 2027.
Bausch Health Acquires DURECT Corporation in Deal Worth up to $413 Million
August 4th 2025

Bausch Health Acquires DURECT Corporation in Deal Worth up to $413 Million

Don Tracy, Associate Editor
The transaction brings larsucosterol, an investigational treatment for alcoholic hepatitis, under Bausch Health’s portfolio as the company advances its liver disease research and development efforts.
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital
August 4th 2025

Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital

Don Tracy, Associate Editor
The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from industry veterans.
Nordic Capital, Permira Reach Agreement to Acquire Bavarian Nordic in $3 Billion Deal
August 4th 2025

Nordic Capital, Permira Reach Agreement to Acquire Bavarian Nordic in $3 Billion Deal

Don Tracy, Associate Editor
Under terms of the deal, Bavarian Nordic shareholders will receive an all-cash offer at a premium, with plans to delist the company and accelerate its global vaccine strategy.